Research programme: peptide-based therapeutics - Phylogica/Johnson & Johnson Research
Latest Information Update: 21 Apr 2010
At a glance
- Originator Johnson & Johnson; Phylogica
- Class Peptide fragments
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 21 Apr 2010 Preclinica development is ongoing in Australia
- 12 Jul 2006 Preclinical trials in Undefined in Australia (unspecified route)